‘ๆ3‰๑@VŠƒtƒVƒ“ƒ|ƒWƒEƒ€

IgAtวŒค‹†‚ฬŒป๓‚ฦซ—ˆ

บ˜a63”N8ŒŽ6“๚@Œ฿Œใ1Žž`6Žž

I ˜iIntroduction) VŠƒ‘ๅŠw‘ๆ2“เ‰ศ r์ณบ

II –ฦ‰u•ก‡‘ฬ‚ฬŠึ—^ Role of IC in pathogenesis VŠƒ‘ๅŠwtŒค–ฦ‰u ’วŽ่@›ู
MB‘ๅŠw‘ๆ1•a— dผGˆ๊

III “ฎ•จƒ‚ƒfƒ‹ Experimental animal model บ˜a‘ๅŠw“กƒP‹u“เ‰ศ ฒ“ก@นŽu

IV –ฦ‰u@Immunology “ŒŠC‘ๅŠw‘ๆ7“เ‰ศ ไ@Gl

V "ฌlIgAtว IgA nephropathy in adults
a) —ีฐ@Clinical features" ŽœŒbˆใ‘ๅ‘ๆ2“เ‰ศ Ž๐ˆไ@‹I

"ฌlIgAtว IgA nephropathy in adults
b) Œ`‘ิ Morphology" VŠƒ‘ๅŠw‘ๆ2“เ‰ศ r์ณบ

VI "ฌŽ™IgAtว IgA nephropathy in childhood
a) —ีฐ@Clinical features" “s—งดฃฌŽ™•a‰@ ˆษ“ก@‘๑

"ฌŽ™IgAtว IgA nephropathy in childhood
b) Œ`‘ิ Morphology" _Œห‘ๅฌŽ™‰ศ ‹g์“ฟ–ฮ

VII Žก—ร@Therapeutic approach

–k—ข‘ๅŠw“เ‰ศ ฌ—ั@–L
VŠƒ‘ๅŠw‘ๆ2“เ‰ศ ‹g“c˜aด